Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
07.03. | Alzinova AB: Bulletin from the Extraordinary General Meeting of Alzinova AB (publ) | 51 | GlobeNewswire (Europe) | The following resolution were passed at the extraordinary general meeting (the "EGM") of Alzinova AB (publ) ("the Company") on 7 March 2025 in Gothenburg.
Long-term incentive program (LTIP 2025:1 for... ► Artikel lesen | |
27.02. | Alzinova AB: Alzinova publishes year-end report 2024 | 86 | GlobeNewswire (Europe) | The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the year-end report for the period January - December, and the fourth quarter, 2024. The full report, which is attached... ► Artikel lesen | |
ALZINOVA Aktie jetzt für 0€ handeln | |||||
03.02. | Alzinova AB: All study participants have completed the final visit in the Phase 1 study | 99 | GlobeNewswire (Europe) | Alzinova AB (publ) (ticker: ALZ) announces that another milestone in the development of the company's vaccine candidate ALZ-101 for Alzheimer's disease has been reached. All study participants have... ► Artikel lesen | |
28.01. | Alzinova AB: Alzinova strategically realigns CMO position to enhance collaboration and drive next development phase | 225 | GlobeNewswire (Europe) | Alzinova AB (publ) (ticker: ALZ) hereby announces that the Company's CMO is stepping down from her role after mutual agreement. The basis is a strategic decision to appoint a CMO in place at the Company's... ► Artikel lesen | |
09.12.24 | Alzinova AB: Alzinova reports positive results from the phase 1b extension part of the ALZ-101 study in Alzheimer's disease | 176 | GlobeNewswire (Europe) | ALZ-101 continues to demonstrate a favorable safety and tolerability profile after at least 84 weeks of study inclusion.The immune response from vaccination with ALZ-101 is robust and long-lasting in... ► Artikel lesen | |
14.11.24 | Alzinova AB: Alzinova publishes interim report January - September 2024 | 134 | GlobeNewswire (Europe) | The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January - September, and the third quarter, 2024. The full interim report, which... ► Artikel lesen | |
10.10.24 | Alzinova's new CEO to "The next six months will be really exciting" | 3 | Cision News | ||
22.08.24 | Alzinova AB: Alzinova publishes interim report January - June 2024 | 95 | GlobeNewswire (Europe) | The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period April - June, and the first half year, 2024. The full interim report, which is... ► Artikel lesen | |
04.06.24 | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Alzinova AB (Record Id 265136) | 487 | GlobeNewswire | With effect from June 05, 2024, the subscription rights in Alzinova AB will be
traded on First North Growth Market. Trading will continue up until and
including June 17, 2024.
Instrument: Subscription... ► Artikel lesen | |
30.05.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 30.05.2024 | 1.618 | Xetra Newsboard | Das Instrument IWY1 US82655M1071 SIFY TECHNO.LTD.ADR IR 10 EQUITY wird cum Kapitalmassnahme gehandelt am 30.05.2024 und ex Kapitalmassnahme am 31.05.2024 The instrument IWY1 US82655M1071 SIFY TECHNO.LTD.ADR... ► Artikel lesen | |
29.05.24 | Alzinova AB: Bulletin from the annual general meeting of Alzinova AB (publ) | 194 | GlobeNewswire (Europe) | Alzinova AB (publ) (the "Company") held its Annual General Meeting on 29 May 2024 in Gothenburg. Below is a summary of the resolutions that were passed. All resolutions were passed with the required... ► Artikel lesen | |
28.05.24 | Alzinova AB: Alzinova publishes interim report January - March 2024 | 338 | GlobeNewswire (Europe) | The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January - March 2024. The full interim report, which is attached in the press release... ► Artikel lesen | |
25.04.24 | Alzinova AB: Kristina Torfgård leaves the CEO position at Alzinova AB in July 2024 | 209 | GlobeNewswire (Europe) | Alzinova's CEO Kristina Torfgård has informed the Board of Directors that she wishes to step down as CEO of the company. Kristina will continue to focus on completing the phase 1b clinical study and... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 36,075 | -0,44 % | Biotech Report: Evotec und Qiagen wenig bewegt | (shareribs.com) Frankfurt / New York 13.03.2025 - Biotech-Aktien bewegen sich im deutschen Handel überwiegend im Plus. Evotec und Qiagen notieren kaum verändert. Biontech klettern. An der Wall Street... ► Artikel lesen | |
TEMPUS AI | 46,470 | +10,21 % | Cathie Wood setzt auf Tempus AI statt auf NVIDIA | ||
EVOTEC | 6,335 | +2,01 % | Evotec Aktie: Haben wir Schlimmeres erwartet? | Das Biotechunternehmen aus Hamburg kämpft mit anhaltender Talfahrt - vom Jahreshoch im März büßte der Wertpapierkurs bereits über 56 Prozent ein. Die Aktie des Hamburger Biotechnologieunternehmens Evotec... ► Artikel lesen | |
BIONTECH | 90,65 | -0,82 % | DAX höher: Heidelberg Materials, Commerzbank, DHL, Rheinmetall, BASF, VW, BioNTech, Oracle ... | Der DAX stand am Freitag im Zuge von Gewinnmitnahmen unter Druck. Er ging am Ende mit einem Minus von 1,8 Prozent auf 23.008,94 Punkten ins Wochenende. Der Start in die neue Woche sieht aber bereits... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 6,305 | +6,14 % | Jim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): 'We're Going To Have To Hold Off' | ||
SPRINGWORKS THERAPEUTICS | 50,94 | +2,35 % | SpringWorks Shares Rise More Than 30% in 3 Months: Here's Why | ||
NUVALENT | 76,59 | +2,83 % | UBS lifts Nuvalent stock rating, maintains $100 price target | ||
SUMMIT THERAPEUTICS | 20,630 | +7,50 % | Summit Therapeutics issues stock options to new employees | ||
BEAM THERAPEUTICS | 24,010 | -4,19 % | Beam Therapeutics Reprots Positive Initial Phase 1/2 Data For BEAM-302 In AATD | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Monday reported positive initial data from its Phase 1/2 study of BEAM-302 for the treatment of alpha-1 antitrypsin deficiency (AATD).AATD... ► Artikel lesen | |
ADMA BIOLOGICS | 18,210 | +1,68 % | Will ADMA Biologics Stock Continue Its Momentum in 2025? | ||
BB BIOTECH | 36,500 | +0,41 % | HV-Kalender: Aktionärs-Versammlungen u.a. bei All for One, BB Biotech, BRAIN Biotech, Datagroup, LS Telcom, MVV Energie, publity, Sparta AG | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 31,850 | -0,87 % | BMO CAPITAL INITIATES AVIDITY BIOSCIENCES WITH OUTPERFORM RATING | ||
REGENCELL BIOSCIENCE | 12,800 | -9,16 % | Regencell Bioscience Stock Surges 126% | ||
MINERALYS THERAPEUTICS | 14,310 | +6,00 % | Mineralys Therapeutics Aktie: Revolutionärer Fortschritt! | Die Aktie von Mineralys Therapeutics verzeichnete einen beeindruckenden Anstieg auf ein 52-Wochen-Hoch von 15,41 US-Dollar, nachdem das Unternehmen vielversprechende Ergebnisse aus seinen klinischen... ► Artikel lesen | |
ONCO-INNOVATIONS | 1,090 | +0,93 % | EQS-Media: Onco-Innovations Ltd.: Bahnbrechende Krebsforschung: Onco-Innovations-CEO über KI und globale Wachstumspläne | EQS-Media / 03.03.2025 / 11:03 CET/CEST
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass CEO Thomas OShaughnessy vor... ► Artikel lesen |